Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes

Research output: Contribution to journalReview ArticleOtherpeer-review

22 Citations (Scopus)


The disappointing results of glucose lowering studies have highlighted the ongoing need to develop new therapeutic strategies to reduce cardiovascular risk in patients with type 2 diabetes. The presence of a range of metabolic abnormalities in diabetic patients presents a number of potential targets for therapeutic intervention. While modulation of peroxisome proliferator activated receptors (PPARs) represents an attractive approach, the results of studies of pharmacological agonists have been variable. The findings of these studies and rationale for development of dual PPAR-a/c agonists will be reviewed.

Original languageEnglish
Pages (from-to)89-94
Number of pages6
JournalDiabetes and Vascular Disease Research
Issue number2
Publication statusPublished - 1 Apr 2012
Externally publishedYes


  • Cardiovascular risk
  • Clinical trials
  • PPAR / agonists
  • Therapeutic strategies

Cite this